This week we are speaking with the chief executive of British drug development company Ellipses Pharma.
Founded in 2018 to create new cancer therapies, the firm is following a unique multimodal approach to clinical development, leveraging a variety of technologies.
That’s not the only way that Ellipses is rethinking drug development. The company uses a consultative model to provide an unbiased vetting process for candidates, with the goal of de-risking initial asset selection.
Ellipses also wants to make sure that capital is invested in the most efficient way, pursuing a portfolio-based strategy which ensures uninterrupted development capital for each asset.
Our guest on the show is Ellipses CEO and co-founder, Dr Rajan Jethwa.